Y-mAbs Therapeutics, Inc. (YMAB) Class Action Notice:

SAN DIEGO, March 08, 2023 (GLOBE NEWSWIRE) --

The Class: Robbins LLP reminds investors that a shareholder filed a class action on behalf of all investors who purchased shares of Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) common stock between October 6, 2020 and October 28, 2022, for violations of the Securities Exchange Act of 1934. Y-mAbs is a clinical-stage biopharmaceutical company focused on developing antibody therapeutics and medicines for the treatment of cancer patients of all ages. The Company's lead product candidate is Omburtamab. According to Y-mAbs, '131I-omburtamab, which is omburtamab radiolabeled with Iodine-131, is currently being studied in several clinical trials including pivotal stage development Study 101 and Study 03-133 for the treatment of pediatric patients who have CNS/LM from NB.”

What Now: Similarly situated shareholders may be eligible to participate in the class action against Y-mAbs. Shareholders who want to act as lead plaintiff for the class must file their papers by March 20, 2023. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. For more information, click here.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

What is this Case аbout: Y-mAbs Therapeutics, Inc. (YMAB) Misrepresented the Viability and Efficacy of its Lead Drug Candidate

According to the complaint, Y-mAbs sought FDA approval of omburtamab through a Biologics License Application first in 2020 and again in 2022, based on a comparison between Study 03-133 performed at Memorial Sloan Kettering Cancer Center (“MSKCC”) and an external cohort comprising data from the Central German Childhood Cancer Registry, or CGCCR, database.

The FDA declined marketing approval of omburtamab in a Refusal to File (RTF) letter dated October 2, 2020, informing Y-mAbs that additional data, including evidence of durable response were necessary to provide the level of evidence needed to support an approval.

Y-mAbs disclosed the existence of the RTF letter in a press release dated October 5, 2020, and in an investor conference call the morning of October 6, 2020, but misrepresented the FDA’s willingness to approve omburtamab for marketing based on the existing clinical trials. In fact, during the class period, Y-mAbs misrepresented to investors that, pursuant to a series of meetings and other communications between Y-mAbs and the FDA, progress was being made that would align with the FDA’s requirement to demonstrate substantial evidence of effectiveness, sufficient for approval of omburtamab, through adequate and well-controlled studies.

To the contrary, the FDA had repeatedly advised the defendants that the FDA was unlikely to grant approval for the marketing of omburtamab based on a comparison between Study 03-133 and CGCCR because of substantial differences in the patient populations, and the absence of tumor response data, and that Study 101 was neither sufficiently advanced nor indicative of efficacy to justify approval. The truth was first disclosed to investors on October 26, 2022, when the FDA published its Briefing Document for an October 28, 2022 Advisory Committee Meeting, and again on October 28, 2022, when the Committee voted 16-0 against recommending approval of omburtamab. On this news, Y-mAbs common shares fell $11.56 per share, to close at $3.61 per share on October 31, 2022.

Contact us to learn more:

Aaron Dumas
(800) 350-6003
adumas@robbinsllp.com
Shareholder Information Form

About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. To be notified if a class action against Y-mAbs Therapeutic, Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contact:
Aaron Dumas
Robbins LLP
5060 Shoreham Pl., Ste. 300
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

https://www.facebook.com/RobbinsLLP/
https://www.linkedin.com/company/robbins-llp/



Y-mAbs Therapeutics, Inc. (YMAB) Class Action Notice:

TIN LIÊN QUAN

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Y-mAbs

SAN FRANCISCO, March 11, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) investors who suffered significant losses...

Caribou Biosciences, Inc. (CRBU) Shareholder Alert: Robbins

SAN DIEGO, Feb. 17, 2023 (GLOBE NEWSWIRE) -- The Class: Robbins LLP reminds investors that a shareholder filed a class action on behalf of persons or...

Vertex Energy, Inc. (VTNR) Shareholder Notice: Robbins LLP

SAN DIEGO, March 09, 2023 (GLOBE NEWSWIRE) -- The Class: Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons...

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders

NEW YORK, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against certain officers and directors of...

Notice of Filing Securities Class Action Against Global

NEW YORK, Feb. 09, 2023 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C. has filed a federal securities class action in the United States District Court...

Beam Therapeutics to Participate in the 43rd Annual Cowen

CAMBRIDGE, Mass., March 01, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic...

Lyra Therapeutics Announces Appointment of John Bishop,

WATERTOWN, Mass., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (the Company or Lyra), a clinical-stage biotechnology company...

THỦ THUẬT HAY

Hướng dẫn cập nhật Android 6.0 và EMUI 4.0 cho Huawei P8 Lite

Hôm nay, người dùng Huawei P8 Lite đã có thể tự động cập nhật lên phiên bản Android mới nhất mà chưa cần phải nhận được thông báo.

Sửa lỗi ISO image extraction failure khi tạo USB Boot bằng Rufus

Khi bạn USB Boot bằng phần mềm Rufus đề cài Windows hoặc các phần mềm khác sẽ xuất hiện thông báo lỗi Error: ISO image extraction failure.

Hướng dẫn cập nhật iOS 11.2 chính thức, sửa lỗi iPhone bị nóng và thoát ứng dụng

iOS 11.2 chính thức được tung ra cho toàn bộ người dùng iPhone trên thế giới.

Cách hiển thị tốc độ mạng trên thanh trạng thái điện thoại Android

Việc hiển thị tốc độ mạng trên thanh trạng thái giúp chúng ta kiểm soát được tốc độ mạng của wifi hoặc 3G nhanh chóng và trực quan nhất. Cùng theo dõi bài viết dưới đây để tìm hiểu tính năng đó nhé.

Cách chuyển dữ liệu từ iPhone/iPad cũ sang thiết bị mới

Nếu bạn có Apple Watch và bạn có một chiếc iPhone mới, hãy hủy ghép nối Apple Watch khỏi iPhone trước đó của bạn trước khi bạn thiết lập thiết bị mới. Tự động ghép nối sẽ tự động sao lưu Apple Watch của bạn để bạn có

ĐÁNH GIÁ NHANH

Đánh giá Galaxy Z Fold3 5G: Flagship xuất sắc của Samsung, rất đáng “đồng tiền bát gạo”

Galaxy Z Fold3 5G là chiếc smartphone màn hình gập nổi bật nhất kể từ khi mẫu điện thoại trang bị màn hình gập ra đời cách đây 3 năm. Theo đánh giá Galaxy Z Fold3 5G của chúng tôi đây là mẫu smartphone xuất sắc nhất

Trên tay OPPO R11s: 6,01-inch tỷ lệ 18:9, camera 20MP, công nghệ AI, pin 3205mAh

Sau khi phát hành của OPPO R11 tháng Sáu năm ngoái, OEM Trung Quốc đã công bố người kế nhiệm tiếp theo là OPPO R11s. Chiếc điện thoại mới của hãng đi theo xu hướng màn hình vô cực, bezels mỏng và đang bắt đầu được bán

“Mổ xẻ” và khám phá bên trong AirPods 3, có nhiều điểm khác biệt so với AirPods Pro

AirPods 3 đã chính thức được ra mắt sau nhiều ngày mong đợi. Thiết kế mẫu tai nghe mới này được đánh giá tương tự AirPods Pro. Tuy nhiên, khi “mổ bụng” và xem bên trong AirPods 3 thì lại có nhiều điểm không giống bản